Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine,
cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Accurate identification of patients likely to achieve long-progression-free survival (PFS) after
chemoimmunotherapy is essential given the availability of less toxic alternatives, such as …

Background The monoclonal anti-CD20 antibody rituximab, combined with
chemotherapeutic agents, has been shown to prolong overall survival in physically fit …

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell
receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib …

Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell …

Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved
outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE …